Buy Gestanin (Allylestrenol 5mg / 25mg) Online - Serum Pharmaceuticals Progestogen Pregnancy Support Therapy
Gestanin (Allylestrenol 5 mg / 25 mg) represents the synthetic progestogen pregnancy support therapy - providing selective progesterone receptor activity for threatened miscarriage prevention, recurrent pregnancy loss management, and premature labor risk reduction across the reproductive age population. Allylestrenol was originally developed by Organon Pharmaceuticals in the Netherlands and introduced clinically in 1961 as Gestanon (and later marketed as Turinal in Eastern Europe), establishing over 60 years of continuous clinical use as a foundational progestogen for pregnancy support indications across Europe, Asia, Latin America, and Eastern Europe. Gestanin on rxshop.md is manufactured by Serum Pharmaceuticals - established Indian pharmaceutical manufacturer with quality manufacturing standards and reproductive medicine focus.
Allylestrenol works as a synthetic 19-nortestosterone derivative progestogen with structural modifications specifically designed to reduce androgenic activity while preserving progestogenic effects for pregnancy support applications. First, allylestrenol binds progesterone receptors in the uterus, cervix, and reproductive tract tissues. Second, allylestrenol reduces uterine myometrial contractility protecting early pregnancy from spontaneous contractions. Third, allylestrenol supports endometrial secretory transformation maintaining decidualization essential for placental attachment. Fourth, allylestrenol stabilizes cervical function supporting cervical integrity during pregnancy. Fifth, allylestrenol provides reduced androgenic activity compared to traditional 19-nortestosterone progestins minimizing virilization concerns during pregnancy therapy.
Gestanin addresses comprehensive pregnancy support indications including threatened miscarriage (vaginal bleeding during early pregnancy with viable fetus), recurrent pregnancy loss (habitual abortion history), premature labor prevention, luteal phase insufficiency, and progesterone deficiency associated with early pregnancy complications. Distinctive advantage of Gestanin is availability in two dose strengths providing complete dosing flexibility - 5 mg for standard prevention and maintenance dosing, and 25 mg for acute threatened miscarriage management and higher-dose protocols. This dual-strength availability enables individualized therapy across the full clinical spectrum.
Gestanin is available in multiple pack sizes at each strength - 30, 60, 90, and 120 tablets for 5 mg strength, and 20, 40, 60, and 80 tablets for 25 mg strength - accommodating different treatment protocols from short cyclic courses through extended pregnancy support therapy. Contraindicated in progestogen-dependent malignancy, severe liver dysfunction, undiagnosed vaginal bleeding, missed abortion, and ectopic pregnancy. Requires obstetric or gynecology specialist supervision during pregnancy therapy.
Free prescription
Discrete packaging
Have questions?
Quality Assurance
- Recurrent Pregnancy Loss: Two or more consecutive miscarriages requiring luteal phase support in subsequent pregnancy attempts;
- Habitual Abortion: Historical term for recurrent early pregnancy loss requiring hormonal supplementation during subsequent gestation;
- Premature Labor Prevention: Prevention of preterm uterine contractions and early labor in high-risk pregnancy patients;
- Luteal Phase Insufficiency: Inadequate corpus luteum progesterone production during second half of menstrual cycle affecting implantation;
- Progesterone Deficiency: Insufficient natural progesterone production affecting fertility menstrual regularity and pregnancy maintenance;
- Pregnancy Support Therapy: Hormonal supplementation during high-risk early pregnancy to reduce miscarriage and support gestation continuation;
- Cervical Function Support: Progestogen supplementation supporting cervical integrity during pregnancy complications;
- High Risk Pregnancy Management: Comprehensive progestogen support during pregnancy complications requiring hormonal supplementation therapy;
- Preterm Labor Risk: Elevated risk of premature delivery requiring uterine relaxation therapy for pregnancy prolongation;
- Early Pregnancy Bleeding: First trimester vaginal bleeding requiring viable pregnancy assessment and progestogen support therapy;
- Endometrial Support: Progestogen supplementation supporting decidualization for embryo implantation and pregnancy maintenance;
- Corpus Luteum Support: Supplementation of corpus luteum progesterone production during early pregnancy before placental takeover;
- Infertility from Luteal Defect: Difficulty conceiving associated with inadequate luteal phase progesterone affecting endometrial receptivity;
- Menstrual Disorders: Cycle irregularities including timing frequency and flow abnormalities responding to hormonal regulation;
- Endometriosis Selected Use: Selected use for endometriosis management with progestogen suppression therapy;
- Uterine Contractility Reduction: Reduction of myometrial contractions protecting early pregnancy from spontaneous contractile activity;
- Placental Function Support: Progestogen supplementation supporting placental development in complicated early pregnancy conditions;
- Post ART Pregnancy Support: Luteal phase and early pregnancy support after assisted reproductive technology cycles;
- Anovulatory Bleeding: Menstrual bleeding disorders from anovulation responding to progestogen cycle regulation therapy.
- Prevents Premature Labor: Reduces preterm contractions and delivery risk in high-risk pregnancies supporting term delivery;
- Reduces Uterine Contractions: Uterine muscle relaxation during threatened miscarriage supporting continued pregnancy development;
- Supports Early Pregnancy: Comprehensive hormonal support during first trimester when miscarriage risk is highest;
- Improves Pregnancy Outcomes: Higher live birth rates in women with recurrent pregnancy loss receiving early progestogen therapy;
- Restores Fertility: Improves conception outcomes in women with documented luteal phase insufficiency through progesterone supplementation;
- Reduced Androgenic Effects: Minimal virilizing effects compared to traditional 19-nortestosterone progestins improving pregnancy safety profile;
- Endometrial Stabilization: Supports secretory transformation and decidualization essential for embryo implantation and pregnancy maintenance;
- Oral Tablet Administration: Simple oral administration avoiding vaginal or injectable progesterone alternatives during pregnancy support therapy;
- Two Strength Dosing Flexibility: 5 mg and 25 mg strengths enable precise dosing across prevention through acute therapy protocols;
- Standard Prevention 5mg Strength: Lower dose enables maintenance and prevention protocols during routine pregnancy support therapy;
- Acute Therapy 25mg Strength: Higher dose enables acute threatened miscarriage management and intensive pregnancy support protocols;
- Cervical Function Support: Supports cervical integrity during pregnancy complications reducing preterm delivery risk substantially;
- Corpus Luteum Supplementation: Provides progestogenic activity when natural corpus luteum production is inadequate for pregnancy support;
- Organon Original Development Heritage: Over 60 years of continuous clinical use with established safety and efficacy documentation;
- Serum Manufacturing Quality: Established Indian pharmaceutical manufacturing standards providing bioequivalent generic quality worldwide;
- Widely Used International Therapy: Preferred pregnancy support progestogen across Europe Asia Latin America and Eastern European medical practice;
- Placental Development Support: Supports early placental development and vascular formation in high-risk pregnancy management;
- Multiple Pack Size Options: 20 to 120 tablet packs accommodate short prevention courses through extended pregnancy support protocols;
- Better Quality of Life: Successful pregnancy support therapy dramatically improves quality of life for couples experiencing pregnancy complications and miscarriage risk.
Generic Gestanin (Allylestrenol 5 mg) Medication guide:
Gestanin (Allylestrenol 5 mg / 25 mg) represents the synthetic progestogen pregnancy support therapy - providing selective progesterone receptor activity for threatened miscarriage prevention, recurrent pregnancy loss management, and premature labor risk reduction across the reproductive age population. Allylestrenol was originally developed by Organon Pharmaceuticals in the Netherlands and introduced clinically in 1961 as Gestanon (and later marketed as Turinal in Eastern Europe), establishing over 60 years of continuous clinical use as a foundational progestogen for pregnancy support indications across Europe, Asia, Latin America, and Eastern Europe. Gestanin on rxshop.md is manufactured by Serum Pharmaceuticals - established Indian pharmaceutical manufacturer with quality manufacturing standards and reproductive medicine focus. Approved for threatened miscarriage, recurrent pregnancy loss (habitual abortion), premature labor prevention, luteal phase insufficiency, and progesterone deficiency. This comprehensive medication guide covers synthetic progestogen pharmacology, tissue-selective mechanism of action, all approved indications, two-strength dosing advantage, contraindications, pregnancy considerations, drug interactions, and long-term therapy considerations for high-risk pregnancy management.
💊 Introduction to Gestanin
Gestanin is a prescription oral medication containing allylestrenol as its active ingredient in two dose strengths (5 mg and 25 mg) as oral tablets. Allylestrenol is a synthetic progestogen chemically derived from 19-nortestosterone with specific structural modifications designed to reduce androgenic activity while preserving progestogenic effects for pregnancy support applications. Allylestrenol was originally developed by Organon Pharmaceuticals in the Netherlands and introduced clinically in 1961 as Gestanon - establishing over 60 years of continuous clinical experience across Europe, Asia, Latin America, and Eastern Europe.
The Gestanin brand available on rxshop.md is manufactured by Serum Pharmaceuticals - established Indian pharmaceutical manufacturer with generic portfolio focused on reproductive medicine, endocrinology, and gynecology products. Serum Pharmaceuticals produces bioequivalent generic allylestrenol under quality manufacturing standards providing cost-effective access to this specialty pregnancy support progestogen.
Allylestrenol occupies a distinctive position in pregnancy support therapeutics due to its unique pharmacological profile. As a 19-nortestosterone derivative with allyl group modification at the C-17 alpha position, allylestrenol provides selective progestogenic activity with substantially reduced androgenic effects compared to parent 19-nortestosterone progestins. This structural modification preserves the uterine muscle relaxation and endometrial secretory support properties essential for pregnancy maintenance while minimizing virilization concerns for the female fetus during pregnancy therapy.
The clinical spectrum of Gestanin focuses on comprehensive pregnancy support indications including threatened miscarriage (vaginal bleeding during early pregnancy with viable fetus), recurrent pregnancy loss (habitual abortion with history of two or more consecutive miscarriages), premature labor prevention in high-risk pregnancy, luteal phase insufficiency affecting fertility and early pregnancy, and general progesterone deficiency associated with early pregnancy complications.
Distinctive advantage of Gestanin is availability in two dose strengths - 5 mg for standard prevention and maintenance dosing, and 25 mg for acute threatened miscarriage management and higher-dose therapy protocols. This dual-strength availability enables complete clinical protocol flexibility from routine maintenance therapy through intensive acute pregnancy support without tablet splitting or combining. Multiple pack sizes accommodate treatment durations from short prevention courses through extended pregnancy support therapy protocols.
🏭 Serum Pharmaceuticals Manufacturer
Serum Pharmaceuticals Credentials
Serum Pharmaceuticals credentials:
- Established Indian pharmaceutical manufacturer with generic portfolio
- Focus on reproductive medicine and endocrinology therapeutic areas
- Quality manufacturing standards ensuring bioequivalent generic quality
- Cost-effective manufacturing enabling accessible pregnancy support therapy pricing
- Regional and international distribution serving Indian and international markets
- Comprehensive gynecology product line including hormone therapy and reproductive medicine
- Bioequivalent generic quality supporting equivalent clinical effects
Manufacturing Quality Standards
Serum Pharmaceuticals produces Gestanin generic allylestrenol with rigorous quality control ensuring bioequivalent allylestrenol content per tablet at each strength (5 mg and 25 mg), pharmaceutical-grade excipients, batch-to-batch consistency, stability testing for shelf-life reliability, and compliance with international pharmacopeia standards. The manufacturing infrastructure provides consistent quality supporting equivalent clinical effects to original Organon brand allylestrenol formulation for pregnancy support therapy applications worldwide.
📜 Organon Brand Heritage
Original Development Timeline
| Year | Development Milestone |
|---|---|
| 1950s | Organon research on 19-nortestosterone progestogen derivatives in Netherlands |
| 1961 | First clinical introduction of allylestrenol as Gestanon by Organon Pharmaceuticals |
| 1960s-1970s | Establishment as leading pregnancy support progestogen across European markets |
| 1970s-1980s | Marketed as Turinal in Eastern European countries and USSR |
| 1980s-1990s | Extensive clinical research validating pregnancy safety and efficacy indications |
| 2000s | Generic allylestrenol became widely available across international markets |
| 2007 | Organon acquired by Schering-Plough - later Merck (post-2009 merger) |
| Present Day | Over 60 years continuous clinical use worldwide except United States |
US Market Status
Allylestrenol US market status:
Allylestrenol was never approved by the FDA for United States market and remains unavailable in America. This absence from US regulatory approval does not reflect safety concerns but rather commercial decisions by Organon regarding US market entry. Allylestrenol continues to be widely prescribed and considered established progestogen therapy across Europe, Asia, Latin America, Eastern Europe, and Middle East with over 60 years of accumulated safety and efficacy data supporting continued global use.
🧬 Understanding Progestogens Class
Progestogen Categories
Progestogen class categories:
- Natural progesterone: Micronized progesterone identical to endogenous hormone
- Progesterone derivatives: Dydrogesterone (retroprogesterone), medroxyprogesterone acetate
- 19-nortestosterone derivatives: Norethindrone, levonorgestrel, allylestrenol, gestodene
- Spirolactone derivatives: Drospirenone with anti-mineralocorticoid activity
- 19-norprogesterone derivatives: Nomegestrol acetate, trimegestone
- Pregnancy support progestogens: Natural progesterone, dydrogesterone, allylestrenol - specifically used for pregnancy indications
Allylestrenol Position Within Progestogen Class
Allylestrenol occupies a distinctive position among 19-nortestosterone derivatives due to structural modification at C-17 alpha position with allyl group that substantially reduces androgenic activity while preserving progestogenic effects. This selective modification makes allylestrenol suitable for pregnancy support indications where androgenic effects on female fetus would be concerning. Compared to other 19-nortestosterone progestins (norethindrone, levonorgestrel) with known androgenic activity, allylestrenol provides safer pregnancy support option while maintaining potent progestogenic effects essential for miscarriage prevention and premature labor management.
🧪 Chemistry of Allylestrenol
Chemical Structure
Allylestrenol has the chemical formula C21H32O with molecular weight approximately 300.48 g/mol. Chemically, allylestrenol is a 19-nortestosterone derivative featuring the characteristic four-ring steroid nucleus with C19 methyl group removed (nor-configuration), 17-beta hydroxyl group, and distinctive allyl group (CH2-CH=CH2) at the C-17 alpha position. This allyl group modification is the key structural feature that reduces androgenic activity while preserving progestogenic effects.
Structural Features
Allylestrenol structural features:
- 19-nortestosterone backbone - characteristic C19-demethylated steroid nucleus
- C-17 alpha allyl group - unique modification reducing androgenic activity
- 17-beta hydroxyl group - preserves progesterone receptor binding activity
- Absent C3 keto group - distinctive feature vs progesterone and other progestogens
- Enhanced oral bioavailability from modified structure
- Selective progestogen receptor activity without significant androgenic binding
- Hepatic metabolism to various inactive and partially active metabolites
- No metabolic conversion to estrogenic or androgenic compounds
🔬 Mechanism of Action
Cellular Mechanism
Allylestrenol mechanism at cellular level:
- Cell membrane diffusion: Allylestrenol passively diffuses across cell membranes due to lipophilic steroid structure
- Progesterone receptor binding: Binds progesterone receptors (PR-A and PR-B) with moderate affinity
- Receptor activation: Ligand-receptor complex undergoes conformational change
- Nuclear translocation: Activated receptor-ligand complex moves into cell nucleus
- DNA binding: Binds progesterone response elements on target gene promoters
- Gene transcription: Regulates transcription of progesterone-responsive genes
- Protein synthesis: Modulates production of proteins mediating progesterone effects
- Selective activity: Reduced binding to androgen receptor due to C-17 allyl modification
Uterine Effects
- Uterine muscle relaxation: Reduces myometrial contractility protecting early pregnancy
- Endometrial secretory transformation: Supports decidualization for placental attachment
- Endometrial receptivity: Prepares endometrium for embryo implantation
- Endometrial stabilization: Reduces early pregnancy bleeding from unstable endometrium
- Progesterone deficiency compensation: Provides progestogenic activity when corpus luteum inadequate
Cervical and Placental Effects
Cervical and placental support effects:
- Cervical mucus modification: Progestogenic effect on cervical mucus composition
- Cervical function support: Supports cervical integrity during pregnancy
- Placental development support: Supports early placental vascular formation
- Immunomodulatory effects: Supports maternal immunological tolerance of fetus
- Uterine artery blood flow: May support placental blood flow during high-risk pregnancy
🔬 Pharmacokinetic Profile
| Parameter | Value | Clinical Significance |
|---|---|---|
| Oral absorption | Rapid and reliable | Not significantly affected by food |
| Oral bioavailability | Good | Predictable clinical effects with oral dosing |
| Time to peak (Tmax) | 1-3 hours | Rapid onset of action |
| Half-life | Approximately 6-8 hours | Supports two to three times daily dosing |
| Protein binding | Moderate | Binds albumin and sex hormone binding globulin |
| Metabolism | Hepatic | CYP450 mediated metabolism to inactive compounds |
| Active metabolites | Minor | Primary progestogenic activity from parent compound |
| Elimination | Renal and fecal | Mixed elimination pathways |
| Steady state | Within 2-3 days | Rapid therapeutic effect assessment |
| Onset of pregnancy support effect | Days to weeks | Progressive symptom improvement with continued therapy |
🤰 Understanding Pregnancy Loss Physiology
Miscarriage Overview
Miscarriage overview:
- Miscarriage definition: Pregnancy loss before 20 weeks gestation
- Overall miscarriage rate: Approximately 15-20 percent of confirmed pregnancies
- First trimester predominance: 80 percent of miscarriages occur in first trimester
- Threatened miscarriage: Vaginal bleeding during early pregnancy with viable fetus - 20-25 percent of pregnancies
- Recurrent pregnancy loss: Two or more consecutive miscarriages - affects 1-2 percent of couples
- Causes: Chromosomal abnormalities, uterine anomalies, endocrine disorders, immunological factors
- Progesterone role: Essential for pregnancy maintenance through early gestation
- Corpus luteum function: Primary progesterone source until placental takeover at 8-10 weeks
Progestogen Role in Pregnancy Support
Progesterone is essential for pregnancy maintenance throughout gestation. During early pregnancy, progesterone is produced by the corpus luteum stimulated by human chorionic gonadotropin (hCG) from the developing embryo. Around week 8-10, the placenta takes over primary progesterone production. Inadequate progesterone during this critical transition can contribute to pregnancy loss. Progestogen therapy including allylestrenol supplements natural progesterone during this vulnerable period, providing uterine relaxation, endometrial support, and cervical stability essential for continued pregnancy.
Preterm Labor Physiology
- Preterm labor definition: Regular contractions before 37 weeks gestation
- Preterm birth impact: Leading cause of neonatal morbidity and mortality worldwide
- Progesterone role: Maintains uterine quiescence throughout pregnancy
- Progesterone withdrawal: Functional progesterone withdrawal triggers labor
- Progestogen therapy rationale: Sustained progestogenic effect prevents premature labor initiation
- Cervical function: Progesterone supports cervical integrity throughout pregnancy
🎯 Approved Pregnancy Support Indications
- Threatened Miscarriage
- Vaginal bleeding during early pregnancy with confirmed viable fetus indicating pregnancy loss risk. Allylestrenol provides progestogenic support supplementing corpus luteum function and reducing uterine contractility. Standard dosing: 25 mg two to three times daily until symptoms resolve, then reduce to 5 mg maintenance dose through first trimester.
- Recurrent Pregnancy Loss (Habitual Abortion)
- History of two or more consecutive miscarriages requiring luteal phase and early pregnancy support in subsequent pregnancy attempts. Allylestrenol supplementation from confirmation of pregnancy through 20 weeks gestation supports pregnancy continuation. Standard dosing: 5 mg two to three times daily from confirmed pregnancy through first trimester or as prescribed.
- Premature Labor Prevention
- Prevention of preterm uterine contractions and early labor in high-risk pregnancy patients. Allylestrenol provides sustained progestogenic effect maintaining uterine quiescence. Standard dosing: 5-10 mg daily continuous during second and third trimester in high-risk patients per obstetric specialist protocol.
- Luteal Phase Insufficiency
- Inadequate corpus luteum progesterone production leading to shortened luteal phase, early pregnancy loss, or infertility. Diagnosis based on luteal phase length under 11 days, low mid-luteal progesterone, or luteal-follicular length discrepancy. Standard dosing: 5 mg twice daily from ovulation through cycle day 25.
- Progesterone Deficiency
- Insufficient natural progesterone production affecting fertility, menstrual regularity, or pregnancy maintenance. Diagnostic evaluation to confirm progesterone deficiency and exclude other causes. Standard dosing: 5-10 mg daily in cyclic or continuous protocol per specialist recommendation.
- Post-ART Pregnancy Support
- Luteal phase and early pregnancy support after assisted reproductive technology (IVF, IUI) cycles. Allylestrenol provides oral alternative to vaginal or injectable progesterone. Standard dosing: 5-10 mg daily from embryo transfer through 10-12 weeks gestation.
🌸 Approved Gynecological Indications
- Menstrual Disorders
- Cycle irregularities including timing, frequency, and flow abnormalities responsive to progestogen regulation. Standard dosing: 5 mg twice daily from cycle days 11-25 for 3-6 cycles.
- Endometriosis Selected Use
- Selected use for endometriosis management with progestogen suppression therapy. Continuous or cyclic dosing depending on pain severity and treatment goals. Multidisciplinary approach with gynecology specialist.
- Anovulatory Bleeding
- Menstrual bleeding disorders from anovulation responding to progestogen cycle regulation. Standard dosing: 5 mg twice daily from cycle days 11-25 for 3-6 cycles establishing regular withdrawal bleeding.
👤 Ideal Patient Selection
Gestanin most appropriate for:
- Women with threatened miscarriage requiring progestogen support during viable early pregnancy
- Women with recurrent pregnancy loss history requiring pregnancy support
- Women with documented luteal phase insufficiency affecting fertility or pregnancy
- High-risk pregnancy patients requiring premature labor prevention
- Post-IVF or IUI patients requiring luteal phase support
- Women with confirmed viable pregnancy on ultrasound
- Patients preferring oral progestogen over vaginal or injectable alternatives
- Women requiring progestogen support without significant androgenic effects concerns
- Patients accepting obstetric or gynecology specialist supervision during therapy
- Women with progesterone deficiency confirmed by clinical evaluation
- Women without contraindications to progestogen therapy
- Patients without severe liver dysfunction or hepatic disease history
- Women without undiagnosed vaginal bleeding requiring evaluation first
🚫 Contraindications
Absolute Contraindications
- Known or suspected progestogen-dependent malignancy
- Undiagnosed abnormal vaginal bleeding - requires diagnostic evaluation first
- Missed abortion - non-viable pregnancy with retained products
- Ectopic pregnancy - allylestrenol does not treat and may delay diagnosis
- Severe liver dysfunction - Dubin-Johnson syndrome, Rotor syndrome, active liver disease
- History of jaundice during previous pregnancy
- Porphyria - progestogens may exacerbate
- Hypersensitivity to allylestrenol or tablet excipients
- Severe pruritus during previous pregnancy
- Herpes gestationis history
Precautions
Use with caution in:
- Depression history: Monitor mood during therapy
- Migraine history: Rare exacerbation reports
- Cardiovascular disease: Minimal cardiovascular effects but monitoring appropriate
- Diabetes mellitus: Monitor glucose control
- Breast disease history: Standard breast health monitoring
- Uterine leiomyomas: May affect fibroid activity minimally
- Mild-moderate hepatic impairment: Dose reduction may be needed
- Renal impairment: Standard dosing usually appropriate
Pregnancy Assessment Requirement
CRITICAL: Pregnancy Assessment Before Therapy
Before initiating allylestrenol for threatened miscarriage or recurrent pregnancy loss, comprehensive pregnancy assessment is essential:
- Ultrasound confirmation: Confirm viable intrauterine pregnancy
- Rule out ectopic pregnancy: Progestogen therapy does not treat ectopic and may delay diagnosis
- Rule out missed abortion: Progestogen therapy inappropriate for non-viable pregnancy
- hCG level assessment: Confirm appropriate pregnancy hormone levels
- Fetal cardiac activity: Document viable fetal heart activity when appropriate gestational age
💉 Comprehensive Dosing Protocols
Indication-Specific Dosing
| Indication | Standard Dose | Duration |
|---|---|---|
| Threatened Miscarriage (acute) | 25 mg two to three times daily | Until symptoms resolve then reduce dose |
| Threatened Miscarriage (maintenance) | 5 mg two to three times daily | Through first trimester |
| Recurrent Pregnancy Loss | 5 mg two to three times daily | From confirmation of pregnancy through 20 weeks |
| Premature Labor Prevention | 5-10 mg daily | Second and third trimester per specialist |
| Luteal Phase Insufficiency | 5 mg twice daily | From ovulation through cycle day 25 |
| Post-ART Pregnancy Support | 5-10 mg daily | From embryo transfer through 10-12 weeks |
| Progesterone Deficiency | 5-10 mg daily | Cyclic or continuous per specialist protocol |
| Menstrual Disorders | 5 mg twice daily | Cycle days 11-25 for 3-6 cycles |
Administration Guidelines
- Take tablets whole with water
- May be taken with or without food
- Space doses evenly through the day for twice or three times daily regimens
- Take at approximately the same times each day
- Do not double dose if missed - resume next scheduled dose
- Continue therapy for prescribed duration - do not discontinue without medical advice
- Pregnancy indications continue as prescribed through first trimester or as directed
- Cyclic indications follow specific cycle day schedule per prescription
- Report unexpected bleeding patterns during therapy
- Maintain regular obstetric or gynecology follow-up appointments
📏 Two-Strength Dosing Advantage
Strength Selection Logic
| Strength | Primary Use | Patient Scenario |
|---|---|---|
| 5 mg | Standard prevention and maintenance | Recurrent pregnancy loss prevention, luteal phase support, gynecological therapy |
| 25 mg | Acute therapy and high-dose protocols | Acute threatened miscarriage, intensive pregnancy support during symptoms |
Dose Titration Approach
Typical dose titration for threatened miscarriage:
- Acute phase (bleeding present): 25 mg two to three times daily (50-75 mg daily total)
- Symptom resolution: Continue 25 mg dosing for several days after bleeding stops
- Reduction phase: Reduce to 5 mg two to three times daily (10-15 mg daily total)
- Maintenance phase: Continue 5 mg dosing through first trimester
- Discontinuation: Gradual taper by end of first trimester or as prescribed
📊 Clinical Effectiveness Data
| Outcome | Response Data |
|---|---|
| Threatened miscarriage pregnancy continuation | Substantial improvement vs placebo in clinical experience |
| Recurrent pregnancy loss live birth rate | Substantial improvement with early progestogen support |
| Premature labor prevention | Reduced preterm delivery rates in high-risk pregnancies |
| Luteal phase support outcomes | Improved conception in documented luteal insufficiency |
| Post-ART pregnancy support | Equivalent to vaginal progesterone with better patient acceptability |
| Time to symptom improvement | Days to weeks for progressive improvement |
| Long-term safety data | Over 60 years continuous international use with established profile |
| Discontinuation rates | Low - excellent tolerability profile |
⚠️ Side Effects
Common Side Effects
- Nausea: Occasional - typically mild
- Headache: Occasional
- Breakthrough bleeding: May occur during initial therapy
- Breast tenderness: Occasional - typically mild
- Abdominal discomfort: Occasional
- Dizziness: Uncommon
- Depression or mood changes: Uncommon
- Fatigue: Uncommon
- Skin reactions: Rare - typically mild
- Menstrual disturbances: Possible early in therapy
- Bloating: Occasional
- Weight changes: Rare - typically modest
Serious Adverse Events
Seek immediate medical attention for:
- Severe allergic reactions: Angioedema, difficulty breathing, throat swelling
- Signs of liver dysfunction: Jaundice, dark urine, severe abdominal pain
- Severe depression or suicidal thoughts
- Severe migraine or persistent headache
- Vision changes
- Unusual heavy or persistent vaginal bleeding
- Complete miscarriage during threatened miscarriage therapy
- Suspected ectopic pregnancy signs during pregnancy therapy
- Persistent breakthrough bleeding not resolving with continued therapy
- Signs of severe skin reactions
🔄 Drug Interactions
| Drug/Substance | Interaction |
|---|---|
| Rifampicin | CYP450 induction may reduce allylestrenol effectiveness |
| Phenytoin, carbamazepine, phenobarbital | Enzyme induction may reduce allylestrenol levels |
| Barbiturates | Enzyme induction may reduce effectiveness |
| St Johns Wort | Herbal enzyme induction may reduce allylestrenol levels |
| Ketoconazole, itraconazole | CYP3A4 inhibition may increase allylestrenol levels |
| Estrogens | Standard combination for HRT - not adverse interaction |
| Antibiotics (broad spectrum) | Minimal effect on allylestrenol |
| Antidepressants | No significant interaction reported |
| Anticoagulants | Standard monitoring appropriate |
| Diabetes medications | Monitor glucose control periodically |
| Grapefruit juice | Potential CYP3A4 inhibition - clinical significance minimal |
🤰 Pregnancy-Specific Considerations
Pregnancy Safety Position
Allylestrenol pregnancy safety features:
- Over 60 years pregnancy use data from extensive international clinical experience
- Reduced androgenic activity minimizes virilization concerns for female fetus
- Extensively used in Europe, Asia for pregnancy support indications
- Established safety profile supporting continued global use
- Not FDA approved in United States (never sought approval)
- Recommended in international guidelines for progestogen indications during pregnancy
- Restoration of progestogenic effect supporting endogenous pregnancy hormones
Fetal Considerations
Allylestrenol structural modification with C-17 alpha allyl group substantially reduces androgenic activity compared to parent 19-nortestosterone. This selective progestogenic activity supports pregnancy while minimizing potential virilization effects on female fetus. Over 60 years of clinical use across Europe, Asia, Latin America, and Eastern Europe has generated extensive safety data supporting appropriate pregnancy indications. However, allylestrenol should be used only when clinical indication supports therapy and prescribing physician determines benefit outweighs any theoretical risk.
Postpartum and Lactation
Postpartum and lactation considerations:
- Allylestrenol may pass into breast milk in small amounts
- Effects on nursing infant not fully established - use with caution during lactation
- Non-breastfeeding postpartum use follows standard indications
- Alternative therapies may be considered during lactation
- Consult prescribing physician regarding continuation during breastfeeding
🛡️ Special Populations
- Reproductive Age Women
- Primary target population for most Gestanin indications. Comprehensive gynecological evaluation required for accurate diagnosis before therapy. Consider fertility goals in treatment planning.
- Pregnant Women
- Primary indications include threatened miscarriage, recurrent pregnancy loss, and premature labor prevention. Extensive international safety database over 60 years supports use in appropriate pregnancy indications. Discontinue if miscarriage complete or ectopic pregnancy diagnosed.
- High-Risk Pregnancy Patients
- Common indication for pregnancy support therapy. Individualized dosing based on clinical presentation and pregnancy stage. Obstetric specialist supervision essential during therapy.
- Recurrent Pregnancy Loss Patients
- Comprehensive evaluation for underlying causes before initiation. Genetic testing, uterine anatomy assessment, endocrine evaluation, and immunological workup appropriate. Individualized therapy planning with reproductive medicine specialist.
- Post-ART Pregnancy Patients
- Oral alternative to vaginal or injectable progesterone for luteal support. Coordinated with reproductive endocrinology protocols. Continue through 10-12 weeks gestation after positive pregnancy test.
- Adolescents
- Use for menstrual disorders, dysfunctional uterine bleeding, or dysmenorrhea when clinically indicated. Pediatric gynecology consultation recommended for young patients.
- Perimenopausal Women
- Common indication for cycle regulation, heavy bleeding management, and transition symptoms. Cyclic dosing establishes predictable bleeding patterns.
- Depression History
- Monitor mood during therapy. Rare mood-related effects reported. Coordinate with mental health providers when appropriate.
- Diabetes Mellitus Patients
- Monitor glucose control periodically. Progestogens can affect insulin sensitivity in some patients. Standard diabetes management continues.
- Hepatic Impairment
- Severe hepatic impairment contraindicated. Mild-moderate impairment - dose reduction may be needed. Monitor liver function periodically.
- Renal Impairment
- Standard dosing generally appropriate. Severe renal impairment - dose adjustment consideration. Monitor renal function.
- Endometriosis Patients
- Selected use for endometriosis management with progestogen suppression. Long-term therapy typically required. Multi-modal approach with gynecology specialist.
📦 Storage and Handling
- Store at room temperature 15-30°C (59-86°F)
- Protect from direct sunlight and moisture
- Keep tablets in original packaging
- Keep out of reach of children and pets
- Do not use past expiration date
- Do not share medication with others
- Return unused medication to pharmacy for proper disposal
- Store in dry area - avoid humid bathrooms
👨⚕️ When to Contact Your Doctor
- Severe allergic reactions: angioedema, difficulty breathing, throat swelling
- Severe skin reactions: rash, hives, blistering
- Signs of liver dysfunction: jaundice, dark urine, severe abdominal pain
- Severe depression or mood changes
- Severe or persistent migraine
- Vision changes
- Suspected ectopic pregnancy signs during pregnancy therapy
- Unusual heavy or prolonged vaginal bleeding
- Complete miscarriage while on threatened miscarriage therapy
- Persistent breakthrough bleeding not resolving with continued therapy
- Suspected pregnancy while on non-pregnancy indication
- Signs of premature labor: regular contractions, pelvic pressure, back pain
- Time for scheduled obstetric or gynecology follow-up appointments
- Starting new medications potentially interacting
- Considering pregnancy or contraception changes
- Persistent side effects affecting daily activities
- Consideration of dose adjustment for effectiveness
- Long-term therapy review appointments
🌟 Key Takeaways
Essential points about Gestanin therapy:
- Gestanin is Serum Pharmaceuticals generic allylestrenol at two strengths (5 mg and 25 mg)
- Original Organon brand identity Gestanon introduced 1961 in Netherlands
- Over 60 years continuous international clinical use
- Synthetic 19-nortestosterone derivative with C-17 alpha allyl group modification
- Substantially reduced androgenic activity vs traditional 19-nortestosterone progestins
- Selective progestogenic activity supporting pregnancy indications
- Never FDA approved for United States market (commercial decision)
- Widely used across Europe, Asia, Latin America, Eastern Europe, Middle East
- Approved for threatened miscarriage, recurrent pregnancy loss, premature labor prevention
- Approved for luteal phase insufficiency and progesterone deficiency
- Approved for post-ART pregnancy support
- Two-strength dosing: 5 mg for prevention/maintenance, 25 mg for acute therapy
- Standard threatened miscarriage: 25 mg 2-3x daily acute, then 5 mg 2-3x daily maintenance
- Standard recurrent pregnancy loss: 5 mg 2-3x daily through 20 weeks
- Take with or without food
- Excellent tolerability compared to many other synthetic progestins
- Low discontinuation rates in clinical experience
- Reduced androgenic activity supports pregnancy safety profile
- Available in multiple pack sizes (20-120 tablets) accommodating all protocols
- CRITICAL: Pregnancy assessment required before initiation - confirm viable pregnancy, rule out ectopic
- Contraindicated in undiagnosed bleeding, missed abortion, ectopic pregnancy, severe liver dysfunction
- Long-term therapy requires obstetric or gynecology specialist supervision
Important Medical Disclaimer: This medication guide provides general information about Gestanin (Serum Pharmaceuticals generic allylestrenol 5 mg and 25 mg tablets) and does not constitute individualized medical advice. Every patient situation is unique and requires evaluation by an obstetrician, gynecologist, reproductive endocrinologist, or qualified healthcare provider before starting progestogen therapy. Gestanin requires comprehensive gynecological workup to establish diagnosis and appropriate indication before therapy initiation. CRITICAL SAFETY: Pregnancy indications require confirmed viable pregnancy assessment with ultrasound documentation excluding ectopic pregnancy or missed abortion before therapy initiation. Threatened miscarriage therapy requires ultrasound confirmation of viable pregnancy with fetal cardiac activity when appropriate gestational age. Recurrent pregnancy loss evaluation should include comprehensive workup for underlying causes including genetic testing, uterine anatomy assessment, endocrine evaluation, and immunological workup. Contraindicated in known or suspected progestogen-dependent malignancy, undiagnosed abnormal vaginal bleeding requiring diagnostic evaluation first, missed abortion (non-viable pregnancy), ectopic pregnancy (progestogen therapy does not treat and may delay diagnosis), severe liver dysfunction, history of jaundice or severe pruritus during previous pregnancy, herpes gestationis history, porphyria, and hypersensitivity. Allylestrenol is not FDA-approved for United States market but has over 60 years of established international clinical use with reduced androgenic activity supporting pregnancy safety profile. Report severe allergic reactions, signs of liver dysfunction, severe depression, severe migraine, vision changes, or suspected ectopic pregnancy immediately. Long-term therapy requires obstetric or gynecology specialist supervision with regular monitoring appointments. Not extensively studied during breastfeeding - use during lactation with caution and prescriber guidance. If you experience concerning symptoms contact your healthcare provider promptly. The information provided here should complement but never replace direct professional medical guidance from your obstetrician, gynecologist, or reproductive medicine specialist.
Gestanin — Frequently Asked Questions
-
What is Gestanin used for?
Gestanin is used to prevent premature labor and miscarriages in pregnant women, especially those with a history of pregnancy loss or threatened miscarriage. -
How does Gestanin work?
Gestanin works by mimicking the effects of natural progesterone, which is essential for maintaining a healthy pregnancy, thereby helping to stabilize the endometrium and reduce the risk of miscarriage. -
Who should take Gestanin?
It is prescribed for women who are at risk of miscarriage or premature labor, often due to a history of such pregnancy complications. -
How is Gestanin taken?
Gestanin is typically taken orally, with the dosage and duration of treatment being determined by the healthcare provider based on the individual's specific needs. -
What are the side effects of Gestanin?
Common side effects may include nausea, vomiting, abdominal discomfort, and bloating. More serious side effects should be reported to a healthcare provider immediately. -
Can Gestanin be used throughout the entire pregnancy?
The use of Gestanin is generally focused on the early stages of pregnancy or as advised by a healthcare provider, depending on the individual's condition. -
Is Gestanin safe?
When used under the supervision of a healthcare provider, Gestanin is considered safe for the treatment of certain conditions during pregnancy. However, like all medications, it should be used with caution.
See all Gestanin questions (32)
More Women's Health Medications
